Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Vistagen Therapeutics (VTGN) Research & Development (2016 - 2025)

Vistagen Therapeutics' Research & Development history spans 13 years, with the latest figure at $14.2 million for Q4 2025.

  • For Q4 2025, Research & Development rose 25.81% year-over-year to $14.2 million; the TTM value through Dec 2025 reached $52.1 million, up 42.4%, while the annual FY2025 figure was $39.4 million, 96.66% up from the prior year.
  • Research & Development for Q4 2025 was $14.2 million at Vistagen Therapeutics, down from $16.0 million in the prior quarter.
  • Across five years, Research & Development topped out at $16.0 million in Q3 2025 and bottomed at $3.9 million in Q3 2023.
  • The 4-year median for Research & Development is $8.9 million (2021), against an average of $8.9 million.
  • The largest annual shift saw Research & Development soared 321.42% in 2021 before it increased 25.81% in 2025.
  • A 4-year view of Research & Development shows it stood at $7.8 million in 2021, then tumbled by 50.49% to $3.9 million in 2023, then surged by 193.56% to $11.3 million in 2024, then increased by 25.81% to $14.2 million in 2025.
  • Per Business Quant, the three most recent readings for VTGN's Research & Development are $14.2 million (Q4 2025), $16.0 million (Q3 2025), and $11.7 million (Q2 2025).